GlassScriptPhysician profile
Kayla Eeg
NPI 1689270225
$3,498.73
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,095 · 2022: $2,042 · 2023: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $1,151.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $592.67 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $289.96 | 2021-2023 | Farxiga |
| Esperion Therapeutics, INC. | $262.51 | 2021-2022 | |
| Abbott Laboratories | $259.63 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $221.51 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $217.73 | 2021-2023 | |
| Amgen INC. | $198.40 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.27 | 2021-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $79.02 | 2022-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.48 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $31.50 | 2021-2022 | |
| Boston Scientific Corporation | $23.96 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Eeg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.